Stock CHRS COHERUS BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.04 USD +5.70% Intraday chart for Coherus BioSciences, Inc. -1.45% -38.74%
Apr. 24 Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting CI
Mar. 20 HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,263 1,252 1,225 777.6 370.8 231.5 - -
Enterprise Value (EV) 1 1,274 1,115 1,217 1,057 726.5 499.9 517.8 221.8
P/E ratio 14.6 x 10.7 x -4.19 x -2.11 x -1.32 x -3.71 x -18.9 x 4.66 x
Yield - - - - - - - -
Capitalization / Revenue 3.55 x 2.63 x 3.75 x 3.68 x 1.44 x 0.88 x 0.65 x 0.51 x
EV / Revenue 3.58 x 2.34 x 3.73 x 5.01 x 2.82 x 1.91 x 1.45 x 0.49 x
EV / EBITDA 11.5 x 7 x -4.67 x -4.17 x -4.9 x -95.9 x 4.27 x 1.21 x
EV / FCF 48,002,592 x 7,589,879 x -31,419,139 x -4,346,684 x -4,147,192 x - - -
FCF Yield 0% 0% -0% -0% -0% - - -
Price to Book 12 x 4.49 x 12.6 x -4.54 x -1.93 x -1.68 x -5.33 x 1.53 x
Nbr of stocks (in thousands) 70,129 72,048 76,785 98,179 111,364 113,498 - -
Reference price 2 18.00 17.38 15.96 7.920 3.330 2.040 2.040 2.040
Announcement Date 2/27/20 2/24/21 2/17/22 3/6/23 3/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 356.1 475.8 326.6 211 257.2 261.9 357.3 456.8
EBITDA 1 111 159.2 -260.4 -253.2 -148.2 -5.215 121.4 183.4
EBIT 1 107.8 156.3 -263.9 -256.9 -203.2 -92.72 -33.57 53.48
Operating Margin 30.27% 32.85% -80.8% -121.72% -78.99% -35.4% -9.4% 11.71%
Earnings before Tax (EBT) 1 92.78 135.7 -287.1 -291.8 -238.3 -60.91 -45.81 39.23
Net income 1 89.83 132.2 -287.1 -291.8 -237.9 -69.41 -19.97 46.4
Net margin 25.23% 27.79% -87.92% -138.24% -92.48% -26.5% -5.59% 10.16%
EPS 2 1.230 1.620 -3.810 -3.760 -2.530 -0.5497 -0.1077 0.4378
Free Cash Flow 26.53 146.9 -38.72 -243.2 -175.2 - - -
FCF margin 7.45% 30.88% -11.86% -115.22% -68.09% - - -
FCF Conversion (EBITDA) 23.9% 92.28% - - - - - -
FCF Conversion (Net income) 29.54% 111.09% - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/27/20 2/24/21 2/17/22 3/6/23 3/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 82.5 73.37 60.12 60.15 45.42 45.35 32.44 58.72 74.57 91.52 83.75 53.68 58.98 64.1 65
EBITDA 1 -31.9 -38.71 -80.16 -43.13 -79.45 -50.44 -50.59 -23.59 -18.32 -57.42 2 -1 8 15 -
EBIT 1 -32.79 -39.55 -80.92 -44.01 -80.45 -51.49 -67.74 -34.54 -32.01 -68.9 -27.58 -33.12 -18.96 -13.05 -
Operating Margin -39.74% -53.9% -134.62% -73.17% -177.11% -113.54% -208.86% -58.83% -42.92% -75.29% -32.94% -61.7% -32.15% -20.35% -
Earnings before Tax (EBT) 1 -38.53 -45.72 -96.08 -50.15 -86.65 -58.87 -75.73 -42.87 -40.02 -79.65 11.54 -35.57 -21.4 -15.48 -
Net income 1 -38.53 -45.72 -96.08 -50.15 -86.65 -58.87 -75.73 -42.87 -39.64 -79.65 10.09 -35.57 -21.4 -15.48 -
Net margin -46.7% -62.32% -159.83% -83.37% -190.76% -129.81% -233.47% -73.01% -53.16% -87.03% 12.05% -66.26% -36.29% -24.16% -
EPS 2 -0.4900 -0.6000 -1.240 -0.6500 -1.110 -0.7600 -0.9600 -0.4900 -0.4100 -0.7100 0.0323 -0.2636 -0.1423 -0.0808 -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/8/21 2/17/22 5/5/22 8/4/22 11/8/22 3/6/23 5/8/23 8/2/23 11/6/23 3/13/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 11 - - 279 356 268 286 -
Net Cash position 1 - 137 8.92 - - - - 9.76
Leverage (Debt/EBITDA) 0.0988 x - - -1.103 x -2.4 x -51.46 x 2.359 x -
Free Cash Flow 26.5 147 -38.7 -243 -175 - - -
ROE (net income / shareholders' equity) 270% 68.5% -73.9% - - - - -
ROA (Net income/ Total Assets) 35.3% 21.2% -18.4% -50.3% -42.8% - - -
Assets 1 254.2 625.3 1,561 580.1 555.2 - - -
Book Value Per Share 2 1.500 3.870 1.270 -1.740 -1.720 -1.210 -0.3800 1.340
Cash Flow per Share - 1.850 -0.5000 -3.110 - - - -
Capex 1 1.82 7.23 1.29 2.04 0.29 0.31 0.35 0.38
Capex / Sales 0.51% 1.52% 0.39% 0.97% 0.11% 0.12% 0.1% 0.08%
Announcement Date 2/27/20 2/24/21 2/17/22 3/6/23 3/13/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Coherus BioSciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.04 USD
Average target price
7.8 USD
Spread / Average Target
+282.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
COHERUS BIOSCIENCES, INC. Stock Coherus BioSciences, Inc.
-38.74% 232M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CHRS Stock
  4. Financials Coherus BioSciences, Inc.